Biofrontera Inc.

NasdaqCM BFRI

Biofrontera Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -29.81%

Biofrontera Inc. EBIT Margin is -29.81% for the Trailing 12 Months (TTM) ending September 30, 2024, a 61.42% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Biofrontera Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -77.26%, a -3.13% change year over year.
Biofrontera Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -74.91%, a 23.13% change year over year.
Biofrontera Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -97.46%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: BFRI

Biofrontera Inc.

CEO	Dr. Hermann Luebbert Ph.D.
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	120 Presidential Way
Employees	83
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years